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Abstract 24 
Introduction 25 
The pathophysiology of heart failure involves activation of several neurohormonal 26 
systems including the renin-angiotensin-aldosterone system. The mineralocorticoid 27 
receptor antagonist spironolactone has been shown to be beneficial in humans and 28 
dogs with heart failure.  29 
The objective of this pilot study was to investigate the efficacy and safety of 30 
spironolactone in cats with heart failure secondary to cardiomyopathy already treated 31 
with furosemide and an angiotensin converting enzyme inhibitor.  32 
Animals 33 
Twenty cats with heart failure due to cardiomyopathy. 34 
Methods 35 
The study was a double blind, randomised, placebo-controlled, multicentre clinical 36 
study assessing the effect of spironolactone on survival and clinical parameters in cats 37 
with heart failure due to cardiomyopathy. The primary endpoint was mortality, defined 38 
as death (spontaneous or by euthanasia) due to cardiac causes. 39 
Results 40 
Twenty cats were enrolled: 9 in the spironolactone group and 11 in the placebo group 41 
of which 56% (5/9) and 0% (0/11) completed the 15-month period respectively. At 42 
inclusion, differences in systemic blood pressure, body condition score, 43 
electrocardiographic abnormalities and LA/Ao ratio suggested disease may be less 44 
severe in the spironolactone group. Twenty-two percent (2/9) of cats in the 45 
spironolactone group and 82% (9/11) in the control group reached the primary 46 
endpoint (Fisher’s exact test, p = 0.0216). No safety issues were identified in either 47 
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group. 48 
Conclusions 49 
This study suggests that spironolactone is well-tolerated and preliminary results 50 
support further investigation to evaluate the efficacy of spironolactone in the treatment 51 
of cats with cardiac failure due to cardiomyopathy.  52 
 53 
Key words: aldosterone; feline; mineralocorticoid receptor 54 
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Abbreviations 56 
ACEi angiotensin converting enzyme inhibitor 
Ao aorta 
CI confidence interval 
HCM hypertrophic cardiomyopathy 
HR hazard ratio 
LA left atrium 
RAAS renin angiotensin aldosterone system 
SD standard deviation 
  57 
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Introduction 58 
Cardiomyopathy is the most common form of heart disease and cause of heart failure 59 
in cats [1]. The pathophysiology of heart failure involves activation of several 60 
neurohormonal systems such as the sympathetic nervous system and the renin-61 
angiotensin-aldosterone system (RAAS) to compensate for the decrease in cardiac 62 
output. Aldosterone is a steroid hormone with mineralocorticoid activity and its major 63 
physiological function is maintaining sodium and potassium balance and blood 64 
pressure control. Binding of aldosterone to the mineralocorticoid receptors in the 65 
kidneys results in an increase in sodium and water reabsorption and potassium 66 
secretion [2]. This phenomenon increases the extra-cellular fluid volume and thus 67 
cardiac preload [3], helping maintain cardiac output in heart failure. Mineralocorticoid 68 
receptor antagonists counteract the retention of sodium and water, and reduce 69 
aldosterone-induced potassium loss [3, 4]. Mineralocorticoid receptors are also found 70 
in cardiomyocytes, coronary endothelial and vascular smooth muscle cells, fibroblasts, 71 
and inflammatory cells, such as macrophages [3]. Chronic activation of the RAAS is 72 
thought to give rise to deleterious effects and worsening of cardiac function, 73 
proarrhythmogenic effects, progression of myocardial fibrosis, vascular remodelling 74 
and endothelial dysfunction [5]. Cardiac fibrosis has been reported in 53% of cases of 75 
feline hypertrophic cardiomyopathy (HCM) [6] and in the myocardial type of feline 76 
restrictive cardiomyopathy [6, 7, 8]. Mineralocorticoid receptor antagonists like 77 
spironolactone have been shown to inhibit aldosterone-induced myocardial fibrosis [5] 78 
and to reduce remodelling of the vascular smooth muscle cells and myocytes [3]. This 79 
action may therefore represent an additional benefit to using these agents in feline 80 
cardiomyopathy. 81 
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Aldosterone receptor blockade has now been shown to be beneficial in humans with 82 
heart failure [9, 10, 11] and in dogs with heart failure secondary to mitral valve disease 83 
[4]. Although there is little published work regarding the treatment of cats in heart 84 
failure, the current recommendations for treatment include the use of diuretics, 85 
angiotensin-converting enzyme inhibitors and antiplatelet drugs if antithrombotic 86 
prophylaxis is required [12, 13]. One study of spironolactone at 2mg/kg per os twice 87 
daily for 4 months in Maine Coon cats affected by HCM conducted by McDonald et al. 88 
in 2008 did not show any improvement in the mitral annular velocity or reduction of the 89 
left ventricular mass [14], four of the 13 treated cats developed severe ulcerative facial 90 
dermatitis. However, this was a short study of only a few months in cats with sub-91 
clinical disease in a related population. The efficacy and safety of spironolactone are 92 
poorly documented in cats with naturally occurring heart disease and congestive heart 93 
failure and warrant further investigation due to the drug’s mode of action, its antifibrotic 94 
properties and its efficacy in heart failure in other species. 95 
The objective of this pilot study was to assess the safety and efficacy of spironolactone 96 
in cats with congestive heart failure secondary to cardiomyopathy being treated in 97 
combination with furosemide and an angiotensin converting enzyme inhibitor (ACEi).   98 
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Animals, Materials and Methods 99 
 100 
Study design 101 
The study protocol was approved by the Ethics Committee of the University of 102 
Nottingham (reference 135 100118) and an Animal Test Certificate was obtained from 103 
the UK Veterinary Medicines Directorate permitting the use of spironolactone in a 104 
species for which it was not licensed. This pilot study was a double blind, randomised, 105 
placebo-controlled, and multicentre clinical study.  106 
 107 
Animals 108 
Client-owned cats with suspected heart failure were screened and those diagnosed 109 
with heart failure fulfilling the inclusion criteria were asked to participate in the trial at 110 
3 different cardiology speciality referral centres in the United Kingdom. Cases were 111 
seen in practice as primary care or referred cases.  112 
 113 
Inclusion criteria 114 
Cats were eligible for inclusion provided the owner had completed and signed an 115 
informed consent form. To be enrolled in the study, cats, of any age, gender and breed, 116 
had to present with congestive heart failure secondary to cardiomyopathy, with 117 
presence of appropriate clinical signs and radiographic evidence of pulmonary 118 
oedema and/or pleural effusion due to left sided or biventricular congestive heart 119 
failure. The cardiomyopathy had to be confirmed by echocardiographic examination 120 
by diploma-holding veterinary cardiologists using currently accepted diagnostic criteria 121 
[8] to identify left ventricular remodelling, left atrial (LA) enlargement from both the  122 
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long (>16.5 mm) and the short axis views with a left atrial (LA)/Aorta (Ao) ratio of > 123 
1.6, and Doppler evidence of diastolic dysfunction.  124 
 125 
Exclusion criteria 126 
Cats with hyperthyroidism, hypertension (Doppler systolic blood pressure >180 127 
mmHg), severe renal disease (serum creatinine >250µmol/l or 2.83mg/dl), congenital 128 
heart disease, non-cardiac systemic disease which may affect the outcome (e.g. 129 
thromboembolic disease or respiratory disease), pregnancy or lactation were 130 
excluded. Cats were also ineligible if a dysrhythmia requiring the use of anti-arrhythmic 131 
medication was evident or in cases of previous or ongoing treatment with pimobendan, 132 
spironolactone or digoxin. 133 
 134 
Randomisation 135 
Cats were randomly allocated to two treatment groups. A randomisation list was 136 
prepared using 2N Softwarec. Case allocation was stratified according to the presence 137 
of hypertrophic cardiomyopathy or not, and then on the need for hospitalisation or not. 138 
This led to the creation of four groups each with a respective randomisation list 139 
composed of blocks of four. 140 
 141 
Study drugs 142 
The animals were randomly allocated to two groups, the treated group received 143 
spironolactone tabletsd and the control group received a placebo identical to 144 
spironolactone in appearance and packaging. Cats were administered from half a 145 
tablet to two tablets per day, i.e. a spironolactone dose between 1.72mg/kg and 146 
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3.33mg/kg per day. In cats, spironolactone is generally used at 2 to 4 mg/kg/day [12, 147 
13]. An allometric extrapolation performed to identify a dose for use in cats provided a 148 
similar theoretical dose of 3.15 mg/kg/day for cats with a mean body weight of 149 
3.75kg. For ease of dosing and administration by the owners, only complete 10mg 150 
tablets or half tablets were administered, resulting in the above mentioned dose (i.e. 151 
1.72mg/kg to 3.33mg/kg per day). Study drugs were administered for sixty weeks, 152 
once daily, with food. The tablet could either be mixed with a small amount of food 153 
offered prior to the main meal or administered directly by mouth after feeding. The 154 
owners were instructed to mark the date and time the medication was given on the 155 
tablet packaging to aid with determination of compliance. 156 
 157 
Concomitant treatments 158 
The cats of both groups had to be concomitantly treated with a combination of 159 
furosemide and ACEi for congestive heart failure (at least from the day of inclusion). 160 
Clopidogrel administration was permitted and left to investigator’s discretion. However, 161 
administration of pimobendan, anti-arrhythmic medication such as diltiazem, digoxin, 162 
lidocaine or beta blockers was forbidden as was the administration of aspirin. Cats 163 
previously or currently treated with spironolactone were also excluded from the study. 164 
Other concomitant medications, therapies or vaccines were allowed as long as 165 
investigators judged they did not interfere with the evaluation of the tested product.  166 
 167 
Visit schedule 168 
Visits and assessments were carried out in accordance with the schedule detailed in 169 
supplemental Table A on-line. 170 
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 171 
Parameter assessment  172 
The clinical parameters recorded were appetite change, dyspnoea, demeanour 173 
change, behaviour change, syncope, ascites and signs of gastro-intestinal disease. 174 
Body condition score was assessed for each cat on a five-point scale. 175 
The radiographic parameters evaluated on plain lateral and dorso-ventral thoracic 176 
radiographs were the Buchanan vertebral heart score [15], presence or absence of 177 
pleural effusion, pulmonary oedema assessed as none, mild or moderate interstitial, 178 
localised or generalised alveolar pattern and the presence or absence of pulmonary 179 
venous congestion.  180 
Systolic blood pressure was determined non-invasively at each visit, using a Doppler 181 
probe and an appropriate sized inflatable cuff according to guidelines established by 182 
the International Society of Feline Medicinee.  183 
The electrocardiographic parameters evaluated were heart rate and rhythm, 184 
ventricular and supraventricular arrhythmias (presence or absence) and any other 185 
abnormality using limb leads in right lateral or sternal recumbency. 186 
The following echocardiographic parameters were evaluated on two-dimensional and 187 
M-mode images: intraventricular septum thickness in diastole and left ventricular free 188 
wall thickness in diastole from the right parasternal long axis view and left ventricular 189 
internal dimension in diastole and in systole, left ventricular shortening fraction, left 190 
ventricular free wall thickness in diastole and in systole, interventricular septum 191 
thickness in diastole and in systole were evaluated with M-mode from a right 192 
parasternal short axis view at the level of the chordae tendinae.  Left atrial diameter 193 
was measured both from right parasternal short and long axis views. Left atrial short 194 
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axis and aortic diameter were used to determine Left Atrium/Aorta ratio (LA/Ao). 195 
Presence or absence of systolic anterior motion of the mitral valve was also assessed 196 
on two-dimensional and M-mode echocardiographic images.  Assessment of mitral 197 
and pulmonary venous inflow patterns and isovolumetric relaxation time using pulsed-198 
wave spectral Doppler echocardiography was used to assess left ventricular diastolic 199 
function. All echoparameters were measured using a concurrent electrocardiogram 200 
trace to assist with appropriate timings except where cats were non-compliant. 201 
An overall assessment of the cat was also completed at each visit by both the 202 
investigator and the owner to assess whether they felt the cat was very well, well, poor 203 
or very poor. 204 
Blood samples were collected at each visit. Biochemistry and haematological variables 205 
were measured and urinalysis was performed. 206 
Treatment compliance was assessed at each follow-up visit by counting the number 207 
of used and unused tablets and checking the dates and times noted by the owner on 208 
the tablet packets. 209 
 210 
Safety assessment 211 
The adverse events were reported during the course of the study by the investigators. 212 
An adverse event is defined as “any observation in animals that is unfavourable and 213 
unintended, and occurs after the use of a veterinary product or investigational 214 
veterinary product, whether or not considered to be product related. It is considered 215 
serious if fatal, life-threatening or resulting in permanent and prolonged signs in the 216 
treated animals”. The adverse events were coded and grouped by organ (System 217 
Organ Class) according to the VeDDRA hierarchical structure, as defined by the 218 
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European Medicines Agencyf. Relationship to the study treatment was assessed by 219 
the investigator at the time of the exam. 220 
 221 
Outcome 222 
The primary endpoint was mortality, defined as death (spontaneous or by euthanasia) 223 
due to cardiac causes. The cause of any spontaneous death was evaluated by the 224 
investigator. 225 
Secondary efficacy endpoints were morbidity-mortality, defined as the combined 226 
incidence of death (spontaneous or by euthanasia) due to cardiac causes and 227 
treatment failure as defined by the addition of a forbidden cardiac drug or premature 228 
removal due to cardiac causes (e.g. thromboembolic disease). 229 
The safety of spironolactone was assessed by describing the frequency and nature of 230 
adverse events and the evolution of haematological, clinical biochemical and urine 231 
parameters in both groups. The results of quantitative blood biochemistry variables 232 
and quantitative haematological variables recorded at inclusion and at each visit was 233 
compared between the two groups. 234 
 235 
Statistical methods 236 
Few studies have prospectively evaluated survival in feline heart failure, consequently 237 
sample size calculation was not feasible and for the purposes of this pilot study the 238 
number of cats to be enrolled was set at 10 animals per group. 239 
The results were analysed with Per Protocol and Intention to Treat populations for the 240 
primary endpoint. For the Intention to Treat analysis, any cat having received the 241 
tested product or the placebo would be included in the efficacy analysis. Only cats for 242 
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which the protocol was strictly respected would be included in the Per Protocol 243 
analysis. The significance threshold was set at p=0.05. Analyses were run on 244 
commercially available softwareg.  245 
The two treatment groups were described and compared on individual criteria on day 246 
0. For qualitative variables chi-square or Fisher’s exact test was used according to 247 
expected values obtained. In case of normality of the data distribution Student’s t test 248 
was used to compare all continuous variables between the two groups. The variance 249 
equality was tested using a Folded F test, in case of unequal variance the 250 
Satterthwaite adjustment was used. In case of non-normality, a non-parametric 251 
Wilcoxon-Mann-Whitney test was used. 252 
If the end of the follow up period for a case was not related to an endpoint or if the 253 
follow up was ongoing at the time of statistical analysis, the cases were censored. 254 
Survival curves were generated by the Kaplan-Meier method. Survival analysis was 255 
performed using a log rank test to compare the survival of the two treatment groups. 256 
The hazard ratio (HR) and its 95% confidence interval (95% CI) were determined 257 
based on a univariate analysis using a Cox model. Bivariate Cox proportional hazard 258 
analysis was also performed. The global percentages of morbidity-mortality or 259 
mortality events at the end of follow-up were compared between groups using Fisher’s 260 
exact test. Statistical significance was declared at a two-sided p-value of ≤0.05.  261 
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Results 262 
Twenty cats were enrolled, 9 in the spironolactone group and 11 in the placebo group, 263 
and followed up for a maximum duration of 15 months, unless death or treatment 264 
failure occurred. Fifteen cats presented with HCM and 7 cats required hospitalisation. 265 
The results of the randomisation is described below in Table 1. 266 
In the spironolactone-treated group, 7 cats (77.8%), had HCM, 1 cat had dilated 267 
cardiomyopathy and 1 cat had unclassified cardiomyopathy. In the placebo-treated 268 
group 8 cats (72.7%) had HCM, 1 cat had dilated cardiomyopathy, 1 cat had restrictive 269 
cardiomyopathy and 1 cat had arrhythmogenic right ventricular cardiomyopathy. There 270 
was no significant difference between the two groups in the echocardiographic 271 
diagnoses. 272 
Among the 20 cats enrolled, no cat experienced a major deviation such as 273 
administration of a forbidden treatment or an evident lack of compliance, therefore, the 274 
Per Protocol population was identical to the Intent To Treat population and the safety 275 
population and includes all enrolled cases. 276 
 277 
Study population at recruitment 278 
The spironolactone and the placebo groups were compared on demographic, clinical, 279 
thoracic radiographic, electrocardiographic, echocardiographic and biochemical 280 
parameters at inclusion. Baseline characteristics for the two groups are described in 281 
Table 2.  282 
 283 
Treatment 284 
Cats in the spironolactone-group received a median dose of 2.83 mg/kg (range 2.08 285 
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– 3.36 mg/kg, inter-quartile range 0.695), doses administered to individual cats are 286 
shown in supplemental Table B on-line. Before inclusion, 17 cats received furosemide 287 
with a time averaged daily dose ± standard deviation (SD) of 5.0 (± 2.9) mg/kg and a 288 
mean duration before enrolment (± SD) of 11 (± 10) days. Of these, 13 received 289 
concomitant benazepril with a time averaged daily dose (± SD) of 0.6 (± 0.4) mg/kg 290 
for a mean period (± SD) of 22 (± 53) days. 291 
When included in the study, the time averaged daily dose (± SD) of furosemide for the 292 
cats in the spironolactone- and in the placebo-treated groups were respectively 3.0 (± 293 
1.2) mg/kg and 4.8 (± 2.3) mg/kg. For benazepril administration, cats received 294 
respectively in the spironolactone- and in the placebo-treated groups 0.4 (± 0.2) mg/kg 295 
and 0.6 (± 0.4) mg/kg as a time averaged daily dose (± SD). 296 
During the study, 8 cats received a potassium supplementation: 5 in the 297 
spironolactone treated group and 3 in the placebo-treated group. 298 
 299 
Primary endpoint 300 
In the spironolactone and control groups, respectively, 56% (5/9) and 0% (0/11) of 301 
cats completed the 15-month period. With respect to mortality due to cardiac causes, 302 
the estimated 15-month survival rate was 78% for the cats treated with spironolactone 303 
and conventional therapy, and 0% for the cats in the control group (log rank test, p = 304 
0.011) (Figure 1). The univariate analysis of treatment demonstrated that the 305 
spironolactone treated cats had a significant risk reduction for reaching the primary 306 
endpoint when compared with the placebo treated cats (HR=0.158; p=0.0226; 95% 307 
CI=0.032–0.772). 308 
In the spironolactone group, 22% (2/9) of cats reached the primary endpoint and 82% 309 
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(9/11) in the control group (Fisher’s exact test, p = 0.0216). Causes of withdrawals not 310 
related to cardiac death were worsening of heart failure and a need for forbidden 311 
concomitant treatment in 2 of 11 cats (18%) receiving the placebo and death or 312 
euthanasia for non-cardiac reasons in 2 of the 9 cats treated with spironolactone 313 
(22%).  314 
Because of the significant difference identified between the groups in left atrial size at 315 
baseline, this parameter was assessed as a covariate in the Cox model. When atrial 316 
size and treatment group were included in a bivariate model, neither had a statistically 317 
significant effect on survival, respectively HR=1.53; p=0.53; 95%CI=0.391-6.240 and 318 
HR= 0.199; p=0.07; 95%CI=0.026-1.063 319 
 320 
Secondary criteria 321 
Morbidity-mortality 322 
Survival analysis showed an estimated 15-month survival rate of 78% in the 323 
spironolactone-treated group significantly different to 0% in the placebo-treated group 324 
(Log Rank test, p=0.0042). The results of univariate analysis on treatment effects 325 
demonstrated a significant risk reduction in the spironolactone treated group as well 326 
(HR=0.136; p=0.0119; 95% CI=0.029–0.644). 327 
There is a significant difference in terms of number of events between the two groups 328 
(p=0.0005) with morbidity-mortality in the placebo group significantly greater than 329 
morbidity-mortality in the spironolactone-treated group (100% versus 22.2%).  330 
 331 
All causes of mortality 332 
Survival analysis showed an estimated 15-month survival rate of 56% in the 333 
17 
 
 
spironolactone-treated group and 0% in the placebo-treated group, which is not 334 
significantly different (Log Rank test, p=0.05). Similarly, the results of the univariate 335 
analysis on treatment effects show no significant risk reduction in the spironolactone 336 
treated group (HR=0.309; p=0.0604; 95% CI=0.091–1.053). No significant difference 337 
between the two groups (p=0.16) with all-cause mortality in terms of number of events 338 
(81.8% versus 44.4%) was demonstrated. Cats with HCM represented 75% of the 339 
population. For this reason, a post-hoc survival analysis on the sub-population of cats 340 
with HCM (n=15, 7 in the spironolactone treated group and 8 in the placebo treated 341 
group) was performed and showed an estimated 15-months survival rate of 100% in 342 
the spironolactone-treated group, significantly different from 0% in the placebo-treated 343 
group (Log Rank test, p=0.0005). There is a significant difference between the two 344 
groups (p=0.0014) with mortality due to cardiac causes in the placebo group 345 
significantly greater than in the spironolactone-treated group (percentage of events at 346 
the end of follow-up: 87.5% versus 0.0%). The univariate analysis of treatment 347 
demonstrated that the spironolactone treated cats had a significant risk reduction for 348 
reaching the primary endpoint when compared with the placebo treated cats 349 
(HR=0.033; p=0.0335; 95% CI=0.001–0.765). 350 
 351 
Safety 352 
Adverse events  353 
In total, 39 adverse events were recorded during the study, with 16 recorded in 7 of 354 
the cats (78%) in the spironolactone-treated group and 23 recorded in 11 of the cats 355 
(100%) in the placebo-treated group. No skin and appendage disorders were recorded 356 
during the course of the study. The adverse events according to the system organ 357 
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class classificationf are available in supplemental Table C on-line; most of the events 358 
were metabolism and nutrition disorders (mainly hypokalaemia), digestive tract 359 
disorders (vomiting) and systemic disorders (loss of appetite, euthanasia or sudden 360 
death). Cardiovascular and respiratory tract disorders occurred primarily in the 361 
placebo-treated group and were usually a consequence of worsening heart failure. 362 
In the spironolactone-treated group, the investigators assessed 44% of the adverse 363 
events as having no relationship to the product and 56% as having a possible or not 364 
assessable relationship. In the placebo-treated group, the percentages were 365 
respectively 39% and 61%. 366 
 367 
Blood and urine parameters 368 
The results for the haematological variables recorded at inclusion and the follow-up 369 
visits for the two groups are shown in Supplemental Table D on-line. 370 
The results for the quantitative blood biochemistry variables recorded at inclusion for 371 
the two groups are shown in Supplemental table E on-line, the mean ± SD of the 372 
results are given. There was a significant difference between the two groups for ALT 373 
activity, albumin and potassium. ALT activity and potassium concentration were higher 374 
and albumin concentration was lower in the placebo-treated group compared to the 375 
spironolactone-treated group. The changes in serum creatinine, urea, potassium and 376 
sodium concentrations in the two groups with time are shown in Figure 2. 377 
No abnormalities were diagnosed as a result of urinalysis that required any specific 378 
interventions or suggested an adverse drug effect on the urinary system. 379 
 380 
 381 
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Blood pressure 382 
The mean systolic blood pressure recorded at each visit from the cats in the two 383 
groups is shown in Supplemental Table F on-line. There was a statistically significant 384 
difference between groups in the systolic blood pressure with that of the placebo-385 
treated group being significantly higher at the first visit (p=0.034). 386 
 387 
Discussion  388 
This study demonstrated that the addition of spironolactone to conventional cardiac 389 
therapy is safe and appears to reduce the risk of cardiac morbidity and mortality in 390 
cats with cardiac failure due to cardiomyopathy when compared with conventional 391 
therapy alone (ACEi plus furosemide). Of the nine cats treated with spironolactone, 392 
five completed the 15 months study compared to none of the 11 cats treated with 393 
placebo. These findings are consistent with survival studies on dogs [4] and humans 394 
[9, 10, 11] with heart failure, although in this study the primary disease, 395 
cardiomyopathy is different from that in the studies on dogs and humans.   396 
However, interpretation of these efficacy data needs to be undertaken with caution 397 
due to the small group sizes involved in this study and to the fact that the 398 
randomisation process, by chance, led to the inclusion of cats with more severe heart 399 
disease (larger left atrial size) in the placebo treated group. The assessment of the 400 
impact of left atrial size on the efficacy of spironolactone in this study suggests that 401 
this parameter should be included as a stratification factor in future studies.  402 
A previous study in Maine Coon cats with familial hypertrophic cardiomyopathy, 403 
spironolactone at 2mg/kg per os twice daily for 4 months did not improve the mitral 404 
annular velocity nor reduced the left ventricular mass. Four of the 13 cats developed 405 
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facial dermatitis severe enough to warrant cessation of treatment [14].  Consequently, 406 
one of the goals of the present study was to gather safety data on long-term use of 407 
spironolactone in a group of out-bred cats to determine whether this problem was as 408 
common in the general population.  No cases of facial dermatitis were seen in the 9 409 
cats treated for up to 15 months in the present study.  Furthermore, the prevalence of 410 
adverse events reported in the spironolactone treated cats was similar to those 411 
reported in the placebo cats suggesting spironolactone is safe to use in cats with 412 
naturally occurring heart failure when treated with furosemide and benazepril. 413 
Interestingly, hypokalaemia was reported both in the spironolactone-treated group (3 414 
cats) and in the placebo-treated group (2 cats). One explanation for the number of 415 
sprironolactone-treated cats having hypokalaemia may be that the mean serum 416 
potassium concentration was significantly lower in the spironolactone group at 417 
baseline when compared to the placebo group. Although these conclusions about the 418 
safety of spironolactone are based on a small group of cats exposed to the drug for a 419 
long period of time, the data are reassuring and support the design of larger pivotal 420 
clinical trials in the future. 421 
Most of the cats in this study (15/20) were suffering with HCM. The results of the 422 
survival analysis in this population may not therefore be generalizable to cats with 423 
other forms of cardiomyopathy. In feline medicine, the classification of myocardial 424 
diseases traditionally follows the World Health Organisation definitions [16] and 425 
guidelines for making these diagnoses are reported in the literature [8, 17, 18]. In 426 
human medicine as well as in veterinary medicine the utility of this traditional 427 
classification is starting to be questioned as more information regarding the natural 428 
history of these conditions becomes availableh [19]. There is increasing evidence that 429 
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human and feline patients may transit between types of disease as the condition 430 
progresses. Different phenotypic expressions of the same condition may exist 431 
(possibly related to genetic heterogeneity [20, 21, 22]) and patients with a similar 432 
cardiac phenotype may have a very different clinical courseh [23]. However, the 433 
encouraging preliminary results on the HCM population would suggest that only cats 434 
with HCM might be enrolled for a future clinical trial, as discussed above, stratified 435 
according to left atrial size. 436 
The activation of the RAAS system as a consequence of a fall in cardiac output 437 
typically occurs in patients with cardiomyopathy of all types as congestive cardiac 438 
failure develops. Consequently there is a degree of commonality in the 439 
pathophysiological consequences of the primary disease in patients with 440 
cardiomyopathy [8] with increased circulating levels of both aldosterone (initially at 441 
least) and angiotensin II demonstrable in patients with cardiac failure. It is likely 442 
therefore, that once cardiac failure has developed a similar pathophysiological process 443 
is involved in the development of cardiomyopathy and the RAAS has been activated 444 
[24]. 445 
No significant diuretic effect of spironolactone has been demonstrated in dogs [25, 26] 446 
and it may be that the observed clinical benefit from associated with spironolactone 447 
use arises primarily from mineralocorticoid blockade effects beyond those of diuresis. 448 
It has been shown in rats [27, 28, 29] and human patients [30, 31, 32] that aldosterone 449 
induces myocardial and perivascular fibrosis and alters the endothelial function of 450 
vessels. Studies performed in human patients with congestive heart failure showed 451 
that these effects are counteracted by mineralocorticoid receptor antagonists [32, 33]. 452 
Cats with hypertrophic cardiomyopathy have been shown to have significant interstitial 453 
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fibrosis and fibrosis of the endocardium [6, 8].  In human medicine there has been a 454 
direct correlation shown between severity of diastolic dysfunction and amount of 455 
myocardial fibrosis as documented on magnetic resonance imaging scans [34].  It has 456 
also been shown in cats that cats with moderate or severe diastolic dysfunction have 457 
a poorer prognosis [35], it is likely that this effect, at least in part is due to myocardial 458 
fibrosis. Mineralocorticoid receptor antagonists like spironolactone have been shown 459 
to inhibit aldosterone-induced myocardial fibrosis [5] and to reduce remodelling of the 460 
vascular smooth muscle cells and myocytes [3]. This action may therefore represent 461 
an additional benefit to using these agents in feline cardiomyopathy where inhibition 462 
of profibrotic and prohypertrophic neurohormones is a reasonable treatment goal in 463 
cardiomyopathies and other cardiac diseases [36]. More recently it has been 464 
suggested that the benefit of mineralocorticoid receptor antagonists now extends to 465 
the early phases of myocardial damage [37] and to heart failure with preserved 466 
ejection fraction, a situation which could describe many cats with cardiomyopathy [38]. 467 
Other recent work also suggests that the effects of angiotensin II and mineralocorticoid 468 
receptor activation in the heart are additive [39]. This observation may be relevant to 469 
the clinical use of ACEi and mineralocorticoid receptor antagonists in combination in 470 
heart failure. 471 
The study has a number of limitations, which are largely a consequence of the fact 472 
that it was a small scale pilot study. No power calculation was done to establish sample 473 
sizes and the number of patients in each group is small. There were differences, some 474 
significant, between the treatment group and the placebo group in some of the 475 
baseline variables. In particular, in the placebo group the body weight at inclusion was 476 
lower than that of the cats in the treatment group and the body condition score of 477 
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placebo-treated cats was significantly lower than that of the cats in the treatment 478 
group. Similarly, in the placebo group there was a significantly higher prevalence of 479 
other abnormalities on the electrocardiogram at presentation. In addition, on 480 
echocardiographic assessment at inclusion into the study there was a significant 481 
difference between the two groups in the LA/Ao ratio. Any future study might include 482 
stratification of cats at inclusion according to severity of heart failure as assessed by 483 
left atrial size or biomarker levels [40]. Another limitation is the fact that no dose 484 
determination study was conducted prior to this pilot study. However, in practice, 485 
veterinarians have been using spironolactone for several years using a dose range of 486 
2 to 4 mg/kg [12, 13] and the allometric approach used in this study provided a similar 487 
dose range (1.72-3.33 mg/kg).  The study does suggest that spironolactone is safe to 488 
use in cats and provides data which would permit better case selection and 489 
stratification and a power calculation to be done for a full clinical trial. 490 
 491 
Conclusion 492 
Spironolactone therapy over a 15-month period in cats with heart failure secondary to 493 
cardiomyopathy was safe to use and demonstrated a potentially beneficial effect when 494 
added to conventional therapy. This finding needs to be confirmed by a large scale 495 
clinical trial, with stratification at inclusion according to parameters which have recently 496 
been demonstrated to be linked to prognosis.  497 
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Figure captions 685 
 686 
Figure 1. Kaplan-Meier survival curves, showing the number of patients 687 
surviving within the populations treated with spironolactone and placebo at 688 
different time points. 689 
   690 
 691 
Figure 2. Serum creatinine, urea, potassium and sodium mean concentrations 692 
for the treatment and placebo groups with time, showing changes in these 693 
parameters over the course of the study. 694 
V = visit number 695 
 696 
 697 
 698 
Table 1. Randomisation of the enrolled cases into the treatment and placebo groups 
according to both stratifications 
 Cats with hypertrophic 
cardiomyopathy 
Cats with other type of 
cardiomyopathy 
Total 
Need for 
hospitalisation 
Spironolactone Placebo Spironolactone Placebo 
Yes 2 3 1 1 7 
No 5 5 1 2 13 
TOTAL 7 8 2 3 20 
 
  
  
 
Table 2. Baseline characteristics of the cats in the treatment and placebo groups at enrolment  
(mean ± standard deviation or number and percentage) 
  Spironolactone Placebo p-value 
Clinical parameters 
 Weight (kg) 4.2 ± 1.3 (9) 3.6 ± 0.9 (11) 0.22 
 Age (years) 7.0 ± 4.9 (9) 10.3 ± 3.5 (11) 0.09 
 Breed 
- Domestic Short Hair 
- Ragdoll 
- Birman 
- Siamese 
8 
- 
- 
1 
 
9 
1 
1 
- 
 
 
 Blood pressure (mm Hg) 115± 22 137 ± 20 0.034 
 Body Condition Score 4.3 ± 1.0 3.3 ± 1.2 0.048 
Electrocardiography 
 Heart rate 185± 28 185±38 0.97 
 Normal sinus rhythm 8/9 (89%) 7/11 (64%) 0.32 
 Ventricular premature complexes 4/9 (44%) 3/11 (27%) 0.64 
 Ventricular tachycardia 1/9 (11%) 0/11 (0%) 0.45 
 Supraventricular premature complexes 0/9 (0%) 2/11 (18%) 0.48 
 Atrial fibrillation 0/9 (0%) 2/11 (18%) 0.48 
 Other arrythmia 0/9 (0%) 1/11 (9%) 1.00 
 Other abnormality* 0/9 (0%) 7/11 (64%) 0.0047 
Echocardiography 
 Interventricular septum thickness in diastole (mm) 5.6± 1.5 (9) 6.2±2.1(11) 0.48 
 LV internal dimension in diastole (mm) 14.5± 4.0 (9) 15.1±2.4(11) 0.72 
 LV free wall thickness in diastole (mm) 6.0± 2.3 (9) 5.7±1.5 (11) 0.68 
 Interventricular septum thickness in systole (mm) 7.7± 1.7 (9) 7.7±2.1 (11) 0.97 
 LV internal dimension in systole (mm) 7.8± 3.6 (9) 9.9±3.4 (11) 0.20 
 LV free wall thickness in systole (mm) 8.2± 2.5 (9) 7.2±2.0 (11) 0.30 
 LV shortening fraction (mm) 45.0± 14.9 (9) 35.4±14.1 (11) 0.15 
 Left Atrium short axis (mm) 17.0± 2.6 (9) 20.0±4.1 (11) 0.077 
 Left Atrium diameter from right parasternal long axis view (mm) 18.5± 2.4 (9) 22.6±5.0 (11) 0.051 
 Aorta diameter (mm) 9.0± 0.8 (9) 8.0±0.6 (11) 0.006 
 Left atrium/Aorta 1.9± 0.3 (9) 2.5±0.6 (11) 0.013 
*Right bundle branch block, negative QRS in lead I but positive in leads II and III, tall and wide P waves, right axis deviation, second degree atrioventricular 
block, ST elevation, left bundle branch block. 
 
  
Supplemental Table A. Visit schedule 
V: visit number; D: day number; W: week number; M: month number 
Visit No. V1 V2 V3 V4 V5 V6 V7 V8 V9 
Day No. 
(Week No.) 
(Month No.) 
D0 D71 
(W 1) 
D282 
(W 4) 
(M1) 
D562 
(W 8) 
(M2) 
D843 
(W 12) 
(M3) 
D1403 
(W 20) 
(M5) 
D2103 
(W 30) 
(M7) 
D2803 
(W 40) 
(M10) 
D4203 
(W 60) 
(M15) 
Clinical examination X X X X X X X X X 
Questionnaire X X X X X X X X X 
Haematology X    X   X X 
Biochemistry X X X X X X X X X 
Packed cell volume X X X X X X X X X 
Thyroid hormone X         
Urine X  X  X X  X X 
Pharmacokinetic sample X X X X X X X X X 
Electrocardiogram X    X   X X 
Blood Pressure X X X X X X X X X 
Echocardiography X    X   X X 
Thoracic Radiographs X       X X 
 
  
Supplemental Table B. Doses of spironolactone administered 
respectively to each cat in the spironolactone-group 
Cat 
Spironolactone 
dose (mg/kg) 
Cat 01 - A 3.26 
Cat 02 - A 2.08 
Cat 03 - A 2.90 
Cat 04 - A 2.33 
Cat 05 - A 2.83 
Cat 06 - A 2.63 
Cat 07 - A 3.03 
Cat 08 - A 2.44 
Cat 09 - A 3.13 
 
  
Supplemental Table C. Number of adverse events in the treatment and placebo groups. 
System Organ Class 
Number of events reported 
Number of cats presenting with the event  
(at least once) 
Total Spironolactone Placebo Total Spironolactone Placebo 
Cardio-vascular system 8 1 7 8 1 7 
Digestive tract 3 3 0 2 2 0 
Ear and labyrinth 1 1 0 1 1 0 
Hepato-biliary 1 1 0 1 1 0 
Metabolism and nutrition 8 6 2 5 3 2 
Renal and urinary 1 0 1 1 0 1 
Respiratory tract 9 1 8 5 1 4 
Systemic 8 3 5 6 2 4 
Total 39 16 23 18 7 11 
 
  
 Supplemental Table D. Range of haematological variables (number of cats) for the cats in the treatment and placebo groups at each visit 
  Haematocrit (%) Packed cell volume (l/L) Total platelet count (X1012/L) Total Red cell count (X109/L) Total white cell count (X109/L) 
Time Spironolactone Placebo Spironolactone Placebo Spironolactone Placebo Spironolactone Placebo Spironolactone Placebo 
V1 31.8 – 44.3 (5) 23.0 – 42.5 (9) 32.0 (1) 27.0 – 42.0 (2) 75 - 757 (5) 65 - 582 (9) 6.1 – 9.7 (5) 4.4 – 9.6 (9) 5.2 – 14.7 (5) 5.5 – 32.1 (9) 
V5 12.8 – 39.4 (4) 22.9 – 39.3 (3) 30.0 (1) 36.0 (1) 131 - 1046 (4) 297 - 378 (3) 3.0 – 9.5 (4) 5.4 – 9.6 (3) 5.3 – 10.1 (4) 6.3 – 14.9 (3) 
V8 29.7 – 34.4 (3) (0) 28.0-32.0 (4) (0) 219 - 703 (3) (0) 7.1 – 9.2 (4) (0) 4.4 – 18.6 (4) (0) 
V9 26.4 – 30.0 (2) (0) 32.0 – 35.0 (2) (0) 310 - 1073 (3) (0) 5.7 – 7.0 (3) (0) 3.4 – 11.9 (3) (0) 
 
  
  
Supplemental Table E. Comparison of the baseline clinical biochemistry parameters of the cats in the treatment and placebo groups at 
enrolment (mean ± SD) 
  Spironolactone Placebo p-value 
 Alkaline phosphatase (U/l) 31.7±14.1 44.2±34.4 0.41 
 Alanine aminotransferase (U/l) 47.0±19.9 89.2±52.3 0.040 
 Albumin (g/l) 32.7±1.6 29.3±3.5 0.044 
 Amylase (U/l) 950±281 1086±304 0.43 
 Chloride (U/l) 114±5 119±4 0.08 
 Cholesterol (mmol/l) 3.9±1.1 4.8±1.2 0.16 
 Creatinine (µmol/l) 154±28 189±56 0.15 
 Globulin (g/l) 45.0±5.8 47.1±11.4 0.68 
 Phosphate (mmol/l) 1.6±0.2 1.5±0.2 0.46 
 Potassium (mmol/l) 3.3±0.2 4.1±0.7 0.028 
 Sodium (mmol/l) 155±8 160±6 0.25 
 Bilirubin (µmol/l) 5.8±4.0 5.6±1.5 0.87 
 Calcium (mmol/l) 2.4±0.1 2.4±0.2 0.88 
 Protein (g/l) 78±6 76±12 0.80 
 Urea (mmol/l) 11.6±7.9 14.5±7.5 0.41 
  
 
 
 
 
 
Supplemental Table F. Systolic blood pressure (median and range) in mmHg (number of cats) in the treatment and placebo 
groups at each visit (V: visit number) 
 V1 V2 V3 V4 V5 V6 V7 V8 V9 
Spironolactone 
120 
85 – 144 
(9) 
121 
106 – 134 
(8) 
128 
120-148 
(7) 
132 
104 – 141 
(7) 
132 
112 – 144 
(7) 
136 
120 – 158 
(5) 
134 
96 – 151 
(6) 
116 
112 – 152 
(5) 
124 
120-128 
(5) 
Placebo 
140 
100 – 168 
(11) 
150 
108 – 166 
(11) 
129 
108 – 200 
(10) 
138 
124 – 176 
(6) 
142 
118 – 180 
(5) 
142 
108 – 148 
(3) 
112 
110 – 114 
(2)   
 
 
 
 
 
 
Group 1: Spironolactone ------------    Group 2: Placebo ------------     
 
Figure 1 
 
  
 
 
  
Creatinine 
(µmol/l) 
 
  
Urea 
(mmol/l) 
 
Potassium 
(mmol/l) 
 
  
Sodium 
(mmol/l) 
 
 
Figure 2 
 
